Pharma — India Patent Cases
967 decisions indexed
Page 24 of 33 · 967 total
Astrazeneca Ab v.Intas Pharmaceuticals Limited, Alkem Laboratories Ltd., Zydus Healthcare Limited & Anr., Torrent Pharmaceuticals Limited, Micro Labs Limited, MSN Laboratories Private Limited, Eris Lifesciences Limited, USV Private Limited, Ajanta Pharma Limited
This Delhi High Court judgment addresses multiple appeals filed by AstraZeneca seeking interim relief to restrain various pharmaceutical companies from infringing its patents. The core issue revolved around whether AstraZeneca was entitled to an immediate injunction while the underlying suits for permanent injunction were pending. The court ultimately dismissed all nine appeals, finding no merit in the appellants' claims.
Ms. Mallika Singh Daughter Of Mr. Narendra Singh and Mr. Parth Pareek Son Of Mr. Prem Prakash Pareek v.Union Of India, State Of Rajasthan, Principal Secretary, Department Of Medical, Health And Family Welfare, Government Of Rajasthan
Petitioners filed a Public Interest Litigation seeking directions to the respondents to ascertain if any vaccine is covered by patents, issue compulsory licenses under the Patents Act, share manufacturing trade secrets, and increase vaccine production capacity. The court dismissed the petition, stating that the issues involved relate to policy decisions to be taken by the respondents.
Franco Indian Pharmaceuticals Pvt Ltd v.Healthyraj Wellness Enterprises & Anr
The Plaintiff, a pharmaceutical company, sought an interim injunction against the Defendants for using the competing mark DIABIT. The court found that the Defendants' mark was structurally, visually, and phonetically almost indistinguishable from the Plaintiff's registered mark DIAVIT, leading to a significant likelihood of confusion.
H. Lundbeck A/S v.Symed Labs Limited
The dispute concerned the alleged infringement of Indian Patent No. 227963 by Symed Labs Limited regarding Vortioxetine/Vortioxetine Hydrobromide. The parties amicably resolved the matter, leading to a decree in terms of the settlement agreement.
Merck Sharp And Dohme Corp v.Amoli Organics Private Limited
Merck Sharp And Dohme Corp filed a suit seeking a permanent injunction and damages against Amoli Organics Private Limited for allegedly making, selling, or dealing in products that infringe its Indian Patent No 209816. The dispute centered on the Sitagliptin API and its salts.
Merck Sharp And Dohme Corp v.Solitaire Pharmacia Private Limited
The plaintiffs filed for an ex-parte injunction against the defendants for infringing their Indian Patent No. 209816 related to SITAGLIPTIN and its pharmaceutically acceptable salts. The court found a prima facie case in favor of the plaintiffs.
Merck Sharp And Dohme Corp v.Yms Laboratories Private Limited
The plaintiffs allege that the defendant is infringing their Indian Patent No. 209816 related to SITAGLIPTIN. They seek an injunction to prevent the defendant from manufacturing or selling infringing products.
Natco Pharma Limited v.Union Of India & Ors.
Natco Pharma Limited filed a writ petition challenging the procedural approach of the Patent Controller, arguing that its application for cross-examination of expert witnesses had not been decided. The court observed the long pendency and directed the Controller to first dispose of Natco's cross-examination application before proceeding with the merits of Novartis' patent application.
Lupin Limited v.Celon Laboraatories Private Limited
Lupin Limited sought an urgent interim injunction in the Bombay High Court against Celon Laboraatories Private Limited for alleged trademark infringement and passing off. The dispute centered on the use of the mark BIVASSA by the defendant, which was deemed deceptively similar to the plaintiff's registered anti-cancer drug mark BEVAZZA. The court found a sufficient prima facie case and granted an ad-interim injunction.
Sun Pharma Laboratories Limited v.Salud Care (India) Private Limited
Sun Pharma Laboratories Limited filed an interim application alleging that Salud Care (India) Private Limited was manufacturing and marketing a pharmaceutical preparation under the mark PROLOMEK, which was confusingly similar to Sun Pharma's registered trademark PROLOMET. The court found a prima facie case of infringement and passing off.
Sun Pharma Laboratories Limited v.Nova Indus Pharmaceuticals And Anr
Sun Pharma Laboratories Limited filed a commercial IP suit alleging trademark infringement and passing off against Nova Indus Pharmaceuticals. The court examined the extreme phonetic and structural similarity between the marks PANTOCID and PANZOCID, finding that there was a sufficient prima facie case.
Franco-Indian Remedies Pvt Ltd v.Unihelix Biotech Pvt Ltd
The Plaintiff filed a suit for trademark infringement and passing off regarding its mark FINATE used in cholesterol control formulations. The Defendant was using the mark FERINATE XT. The Court found a prima facie case due to the confusing similarity between the marks, leading to an interim injunction favoring the Plaintiff.
Ajanta Pharma Limited v.Uniray Life Sciences
Ajanta Pharma Limited filed an interim application alleging that Uniray Life Sciences was using the competing mark ACNO GEL, which infringed upon Ajanta's registered trademarks (ACNO and ACNO-C) used for acne treatment. The court found a sufficient prima facie case and granted an ad-interim injunction.
Pfizer Products Inc v.Unichem Laboratories Limited
The Plaintiffs filed a suit for permanent injunction against the Defendant for infringement of Indian Patents. The parties reached a settlement and withdrew the suit and counter-claim.
Novartis Ag v.Windlas Biotech Pvt Ltd
The case involves a patent infringement dispute where Novartis AG claims that Windlas Biotech Pvt Ltd is infringing on their Indian Patent No. 229051 related to a pharmaceutical composition comprising Sacubitril + Valsartan. The court has previously issued an interim order restraining the defendants from using the infringing product.
Novartis Ag v.Eris Lifesciences Limited
The case involves a patent infringement dispute where Novartis AG claims that Eris Lifesciences Limited is infringing on their Indian Patent No. 229051 related to a pharmaceutical composition comprising Sacubitril + Valsartan.
H. Lundbeck A/S v.Hetero Drugs Limited
The suit sought an injunction against Hetero Drugs Limited concerning Indian Patent 227963 for Vortioxetine Hydrobromide. The parties reached a settlement regarding IA No. 2333/2021, allowing the defendant to export products under Section 107A of the Patents Act, provided strict conditions are met.
Merck Sharp And Dohme Corp v.Indilina Pharmaceuticals
Merck Sharp & Dohme Corp (Plaintiff) filed a suit seeking an injunction against Indilina Pharmaceuticals (Defendant) for infringing their patent (IN'816) covering the compound Sitagliptin. The Plaintiffs alleged that the Defendant was offering tablets of Sitagliptin for sale in tenders. The Court granted interim relief restraining the Defendant from any infringing activities and directed disclosure of profits.
Dr.Reddys Laboratories Limited v.Eros International Media Limited And Anr.
Dr. Reddy's Laboratories sought an urgent interim injunction to prevent the release of a feature film, 'Haathi Mere Saathi,' alleging that its brand mark 'DRL' was being used in a derogatory manner within the movie plot. The Delhi High Court ultimately dismissed the plaintiff's application, finding that Dr. Reddy's failed to meet the three-pronged test for granting an injunction. The court held that the balance of convenience favored the defendants due to their substantial investment in the film production.
Novartis Ag v.Eris Lifesciences Limited
The plaintiffs seek an injunction to restrain the defendant from manufacturing and selling a pharmaceutical composition that allegedly infringes their patent.
H. Lundbeck A/S v.Hetero Drugs Limited
The dispute involves H. Lundbeck A/S challenging Hetero Drugs Limited's export activities, which are claimed by the defendants to be permissible under Section 107A of the Patents Act for R&D purposes. The court issued an interim order allowing the defendants to continue exports to seven specified entities while addressing objections raised by the plaintiff.
Centaur Pharmaceuticals Pvt Ltd v.BRD Medilabs & Anr
Centaur Pharmaceuticals Pvt Ltd filed a Commercial IP Suit against BRD Medilabs & Anr regarding trademark infringement. The court decreed the suit in specific terms, requiring the defendants to apply for the cancellation of their registered mark 'Sanaret Labs' and withdraw their service mark application within four weeks.
H. Lundbeck A/S v.Hetero Drugs Limited
H. Lundbeck A/S filed a suit against Hetero Drugs Limited regarding alleged infringement of Patent IN227963, which covers Vortioxetine Hydrobromide. During the hearing, the defendants asserted that they were not commercially launching any product and were using the substance solely for regulatory and R&D purposes.
Merck Sharp And Dohme Corp & Anr v.Actis Generics Pvt Ltd
The Plaintiffs, Merck Sharp & Dohme Corp. and Sun Pharmaceutical Industries Ltd., filed a suit seeking an injunction against Actis Generics Pvt Ltd for infringing Patent No. IN'816, which covers the compound Sitagliptin. The court examined the prima facie case and found that the Defendant was distributing and selling infringing Sitagliptin API without authorization.
Eli Lilly And Company v.Natco Pharma Limited
This case involved a suit for alleged patent infringement. The defendants filed applications seeking condonation of delay in filing their written statements, citing difficulties caused by the COVID-19 pandemic and general disruptions to legal processes. The court allowed these applications, condoning the delay.
Astrazeneca Pharma India Limited v.The National Pharmaceutical Pricing Authority & Ors.
Astrazeneca challenged several orders and notifications issued by NPPA regarding overcharging on its drug, OSIMERTINIB (TAGRISSO). The petitioner argued that the drug is patented and qualifies for a five-year exemption from price controls under DPCO, 2013. The Court directed NPPA to reconsider the matter afresh after taking into account the data supplied by the petitioner.
Plaintiff No. 1 v.Defendants
The plaintiffs, owners of two patents covering the compound LINAGLIPTIN and its derivatives, filed a suit alleging that the defendants were manufacturing LINAGLIPTIN tablets under the brand name BRLENTA-5 without consent. The court found a prima facie case for injunction.
Merck Sharp And Dohme Corp v.Chiral Biosciences Limited
The plaintiffs, Merck Sharp And Dohme Corp, filed a suit alleging infringement of their Indian Patent No. 209816 covering Sitagliptin, a DPP-4 inhibitor used to treat Diabetes Mellitus Type II. The court issued an order granting an ex parte ad interim injunction restraining the defendant from manufacturing or dealing in infringing products until further hearing.
Centrient Pharmaceuticals Netherlands B.V. v.Dalas Biotech Limited
The plaintiffs filed an application seeking discovery through interrogatories in a suit alleging infringement of their patent for Amoxicillin Trihydrate. The plaintiffs argued that the defendant's process description was ambiguous and evasive, hiding the use of immobilized enzymes and specific acids. However, the court dismissed the application, finding it amounted to a roving inquiry and stating that the issues could be addressed through cross-examination.
Pharmacyclics Llc. v.Alkem Laboratories Ltd.
The Delhi High Court addressed a commercial suit filed by Pharmacyclics Llc. against Alkem Laboratories Ltd., alleging infringement of Patent IN 262968. The court noted that the plaintiffs had other related suits pending before different benches regarding the same patent. Consequently, the court ordered the listing of the current suit for further consideration.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.